People / Tony Subketkaew
placeholder image

Tony Subketkaew

As a former Regulatory Counsel with the FDA, Tony assists clients with a wide range of FDA and advertising matters. In addition to his previous experience counseling FDA leadership and program offices on import and operational policy while a part of FDA’s Office of Regulatory Affairs, Tony began his career at the FDA as part of the Presidential Management Fellowship in the Center for Food Safety and Applied Nutrition, also completing a detail in FDA's Office of Chief Counsel.

Tony’s advertising law experience covers FDA-adjacent issues in addition to traditional FDA matters. His work in this space has included assisting with advertising litigation, preparing both responses and challenges before the National Advertising Division (NAD) of the Better Business Bureau, Proposition 65 compliance reviews, and assessing marketing claims.

Tony’s interest in the food industry began prior to his work at FDA: he was actively involved in his high school FFA chapter and received an honors degree in Agricultural Economics from Oklahoma State University. Prior to law school, Tony taught elementary school in Baltimore City as a member of Teach For America.

Professional Recognition

  •  Included in the "Ones to Watch" category of Best Lawyers in America, Woodward/White, Inc., 2021-2022
Show More
Expand All
Professional Affiliations and Engagements
  • Food and Drug Law Institute
  • Asian Pacific American Bar Association
  • Oklahoma State University Alumni Association, Chapter President, Washington, D.C.


J.D., Ohio State University Moritz College of Law, 2013

M.A., Johns Hopkins University, 2010

B.S., Oklahoma State University, 2008, cum laude




District of Columbia


Press Release
Haynes Boone Represents Strides Pharma Science in $24 Million Acquisition
August 20, 2021

A Haynes and Boone, LLP deal team led by Simin Sun and Jeff Wolfson is representing Strides Pharma Science Limited in a $24 million acquisition announced Aug. 6, 2021. Strides announced that its wholly owned subsidiaries have entered into definitive agreements with subsidiaries of Endo International to acquire its manufacturing facility in New York and various Abbreviated New Drug Applications (AN [...]